Blood Test Detects Patients at Risk for Diabetes

It is a novel blood test for prediabetes that reflects insulin resistance. The test is based on three recently identified nonglycemic biomarkers and insulin, and detects progression to prediabetes earlier than traditional glycemic measures such a hemoglobin A1C.

Metabolon (Research Triangle Park, NC, USA) is showcasing the Quantose test, which is a metablomics-driven diagnostic, at the American Association for Clinical Chemistry Lab Expo (AACC) being held from July 15-19, 2012, in Los Angeles (CA, USA). Two posters highlighting the clinical utility of Quantose are being presented at the Expo.

In a poster, the clinical utility of Quantose as a simple, practical measure of insulin resistance will be demonstrated in this poster session with data highlighting the correlations between Quantose and other known risk factors for type 2 diabetes and cardiovascular disease.

In a second poster, differences in insulin resistance using HbA1c and metabolic markers Alpha-hydroxybutyrate, Linoleoyl-GPC, and Oleate are described. This clinical study was performed at the University of North Carolina (Chapel Hill, NC, USA) comparing Quantose metabolic markers to hemoglobin A1C for the ability to detect insulin resistance. Data include the finding that Quantose scores closely track worsening dysglycemia as defined by hemoglobin A1C, but that Quantose also identifies a substantial subset of patients as insulin resistant despite hemoglobin A1C values within the normal range (<5.7%). The clinical study was performed at the University of North Carolina, (Chapel Hill, NC, USA) comparing Quantose metabolic markers to hemoglobin A1C for the ability to detect insulin resistance.

Metabolon, Inc. has developed technology to quickly identify and measure all biochemicals in a biological sample. This method provides a precise understanding of disease etiology and drug action, and advances personalized medicine.

Related Links:
Metabolon
University of North Carolina